NCT02173704已完成3 期
A Phase 3, Open Label, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants in Taiwan.
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 225
- 试验地点
- 3
- 主要终点
- Percentage of Subjects With Human Serum Bactericidal Assay (hSBA) Titer ≥ 1:4 Against Neisseria Meningitidis Serogroup B Strains
研究概览
简要总结
Assess the safety and immunogenicity of a 3-dose schedule (at 2, 4, 6 months) of GSK Biologicals' Meningococcal B recombinant vaccine followed by a booster at 12 months when concomitantly administered with routine vaccines in healthy infants in Taiwan.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 55 Days 至 89 Days（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •healthy 2-month old infants (55-89 days, inclusive), who were born after full term pregnancy with an estimated gestational age ≥ 37 weeks and a birth weight ≥ 2.5 kg;
- •for whom a parent/legal guardian has given written informed consent after the nature of the study has been explained;
- •available for all the visits scheduled in the study;
- •in good health as determined by medical history, physical examination and clinical judgment of the investigator.
排除标准
- •History of any meningococcal vaccine administration;
- •Prior vaccination with any Diphtheria, Tetanus, Pertussis (acellular or whole cell), Polio (either Inactivated or Oral), Haemophilus influenzae type b (Hib), Pneumococcal, MMR or varicella antigens;
- •Previous ascertained or suspected disease caused by N. meningitidis;
- •Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis;
- •History of severe allergic reaction after previous vaccinations or hypersensitivity to any vaccine component;
- •Significant acute or chronic infection within the previous 7 days or body temperature higher or equal to 38C degrees within the previous day;
- •Antibiotics within 6 days prior to enrollment;
- •Any serious chronic or progressive disease according to the judgment of the investigator (e.g., neoplasm, insulin dependent diabetes mellitus Type I, cardiac disease, hepatic disease, progressive neurological disease or seizure, either associated with fever or as part of an underlying neurological disorder or syndrome, autoimmune disease, HIV infection or AIDS, or blood dyscrasias or diathesis, signs of cardiac or renal failure or severe malnutrition);
- •Known or suspected impairment/alteration of the immune system, immunosuppressive therapy, use of systemic corticosteroids or chronic use of inhaled high-potency corticosteroids since birth;
- •Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation;
- •Receipt of, or intent to immunize with any other vaccine(s) (with the exception of rotavirus vaccine, influenza vaccine and second HepB vaccine), within 28 days prior and throughout the study period. Furthermore, subjects must have received HepB vaccine preferably at 0, 1 month of age, with the second dose at least 14 days prior to study vaccination. Influenza vaccine should be administered at least 14 days before or 14 days after study vaccination; Rotavirus vaccine may be administered during the study as per local practice.
- •Participation in another clinical trial since birth or planned for during study;
- •Family members and household members of research staff;
- •Any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
结局指标
主要结局
Percentage of Subjects With Human Serum Bactericidal Assay (hSBA) Titer ≥ 1:4 Against Neisseria Meningitidis Serogroup B Strains
时间窗: At Day 1 and at one month after third vaccination (Day 152)
Percentage of subjects with hSBA titer ≥ 1:4 at 1 month after third vaccination (at 7 months of age) against the indicator strains H44/76, 5/99, NZ98/254 and strain M10713 when Bexsero® was given concomitantly with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13® and Engerix-B®).
Percentage of Subjects With Human Serum Bactericidal Activity (hSBA) Titer ≥ 1:5 Against Neisseria Meningitidis Serogroup B Strains
时间窗: At Day 1 and at one month after the third vaccination (Day 152)
Percentage of subjects with hSBA titer ≥ 1:5 at 1 month following the third vaccination (at 7 months of age) against the indicator strains H44/76, 5/99, NZ98/254 and strain M10713 when Bexsero® was given concomitantly with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13® and Engerix-B®).
次要结局
- hSBA Geometric Mean Ratios (GMRs) Against Neisseria Meningitidis Serogroup B Strains.(At Day 1, Day 152, Day 305 and Day 335)
- Number of Subjects Reporting Solicited Systemic Adverse Events (AEs) After Receiving Bexsero® Vaccine With Routine Vaccine or Routine Vaccines Alone, at 2, 4, 6 and 12 Months of Age.(From day 1 (6 hours) to day 7 after each vaccination)
- Number of Subjects Reporting Serious Adverse Events (SAEs), Medically Attended AEs (MAEs) and AEs Leading to Premature Withdrawal and Death and AEs Leading to Hospitalization.(Throughout the study period (Day 1 to Day 335))
- Percentage of Subjects With hSBA Titer ≥ 1:5 Against Neisseria Meningitidis Serogroup B, When Bexsero® Booster Was Given With Routine Vaccines (Priorix® + Varilrix® Vaccines)(At Day 305 and Day 335)
- Number of Subjects Reporting Solicited Local Adverse Events (AEs) After Receiving Bexsero® Vaccine With Routine Vaccine or Routine Vaccines Alone, at 2, 4, 6 and 12 Months of Age.(From day 1 (6 hours) to day 7 after each vaccination (1st, 2nd, 3rd and 4th vaccination))
- Number of Subjects Reporting Solicited Systemic AEs After Receiving Priorix® and Varilrix® Routine Vaccines (With and Without Bexsero® Vaccine) at 12 Months of Age.(From Day 1 to Day 28 after vaccination)
- Number of Subjects Reporting Unsolicited Adverse Events After Receiving Bexsero® Vaccination With Routine Vaccines(From day 1 to day 7 after each vaccination)
- Percentages of Subjects With hSBA Titers ≥1:8 Against Neisseria Meningitidis Serogroup B, When Bexsero® Vaccine Was Given With Routine Vaccines(At Day 1,Day 152,Day 305, Day 335)
- hSBA Geometric Mean Titers (GMTs) Against Neisseria Meningitidis Serogroup B Indicator Strains, When Bexsero® Vaccine Was Given With Routine Vaccines(At Day 1, Day 152, Day 305 and Day 335)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
3 期
Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)Pneumococcal InfectionsNCT04016714Merck Sharp & Dohme LLC1,191
已完成
3 期
Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young AdultsInfections, MeningococcalNCT04502693GlaxoSmithKline3,657
已完成
3 期
A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2012/2013 in People Aged 18 Years and AboveInfluenzaNCT01607112GlaxoSmithKline119
已完成
3 期
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster VaccineHerpes ZosterNCT05047770GlaxoSmithKline2,013
Unknown
1 期
Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity PEK Fusion Protein VaccineCervical Intraepithelial NeoplasiaNCT01880411HealthBanks Biotech Co., Ltd.15